AR089799A2 - Composicion que comprende enzimas y usos para la fabricacion de una composicion para tratar o disminuir el riesgo de infecciones del tracto digestivo - Google Patents

Composicion que comprende enzimas y usos para la fabricacion de una composicion para tratar o disminuir el riesgo de infecciones del tracto digestivo

Info

Publication number
AR089799A2
AR089799A2 ARP130100218A ARP130100218A AR089799A2 AR 089799 A2 AR089799 A2 AR 089799A2 AR P130100218 A ARP130100218 A AR P130100218A AR P130100218 A ARP130100218 A AR P130100218A AR 089799 A2 AR089799 A2 AR 089799A2
Authority
AR
Argentina
Prior art keywords
composition
food
composition according
clauses
enzyme
Prior art date
Application number
ARP130100218A
Other languages
English (en)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22617824&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR089799(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of AR089799A2 publication Critical patent/AR089799A2/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/47Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23KFODDER
    • A23K20/00Accessory food factors for animal feeding-stuffs
    • A23K20/10Organic substances
    • A23K20/189Enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/465Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y301/00Hydrolases acting on ester bonds (3.1)
    • C12Y301/04Phosphoric diester hydrolases (3.1.4)
    • C12Y301/04011Phosphoinositide phospholipase C (3.1.4.11)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y302/00Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01078Mannan endo-1,4-beta-mannosidase (3.2.1.78), i.e. endo-beta-mannanase
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Animal Husbandry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Fodder In General (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

Una composición oral para el tratamiento o disminución del riesgo de una infección del tracto digestivo de un animal, que comprende: (i) una enzima endo-1,4-b-D-mananasa, y ii) un vehículo fisiológicamente aceptable para dicha enzima, donde dicha composición no contiene un agente anti-infeccioso diferente de dicha enzima. Reivindicación 2: La composición acorde con la cláusula 1, caracterizada porque dicha composición es un alimento. Reivindicación 3: La composición acorde con la cláusula 1 ó 2, caracterizada porque dicho animal es un animal para producción de carne. Reivindicación 4: La composición acorde con cualquiera de las cláusulas 1 - 3, caracterizada porque dicha composición comprende un estabilizador, un portador carbohidrato ó un conservante. Reivindicación 6: La composición acorde con cualquiera de las cláusulas 1 - 5, caracterizada porque dicha composición comprende un portador carbohidrato y dicho portador carbohidrato se selecciona del grupo que consiste en xilosa, fructosa, glucosa, sorbitol, y maltotriosa. Reivindicación 8: La composición acorde con cualquiera de las cláusulas 1 - 7, caracterizada porque dicho vehículo es un alimento en el cual se incorpora la enzima. Reivindicación 9: La composición acorde con cualquiera de las cláusulas 1 - 8, caracterizada porque dicho vehículo es un alimento y dicho alimento es un alimento para animales que comprende material de granos, una fuente de proteína, vitaminas, aminoácidos o minerales. Reivindicación 14: La composición acorde con cualquiera de las cláusulas 1 - 13, caracterizada porque dicha enzima es producida por Bacillus lentus designado como ATCC 55045. Reivindicación 17: La composición acorde con cualquiera de las cláusulas 1 - 14, caracterizada porque dicha composición es un alimento y dicha enzima está presente en una cantidad seleccionada de 3 U/0,45359237 Kg (3 U/lb) de alimento, 30 U/0,45359237 Kg (30 U/lb) de alimento, o 90 U/0,45359237 Kg (90 U/lb) de alimento.
ARP130100218A 1999-12-10 2013-01-24 Composicion que comprende enzimas y usos para la fabricacion de una composicion para tratar o disminuir el riesgo de infecciones del tracto digestivo AR089799A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16993599P 1999-12-10 1999-12-10

Publications (1)

Publication Number Publication Date
AR089799A2 true AR089799A2 (es) 2014-09-17

Family

ID=22617824

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP000106541A AR026764A1 (es) 1999-12-10 2000-12-07 Tratamiento enzimatico para infecciones.
ARP130100218A AR089799A2 (es) 1999-12-10 2013-01-24 Composicion que comprende enzimas y usos para la fabricacion de una composicion para tratar o disminuir el riesgo de infecciones del tracto digestivo

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP000106541A AR026764A1 (es) 1999-12-10 2000-12-07 Tratamiento enzimatico para infecciones.

Country Status (31)

Country Link
US (2) US6780628B2 (es)
EP (1) EP1239872B1 (es)
JP (1) JP4871473B2 (es)
KR (1) KR100639746B1 (es)
CN (3) CN1433319A (es)
AR (2) AR026764A1 (es)
AT (1) ATE481981T1 (es)
AU (1) AU782831B2 (es)
BR (1) BRPI0016231B8 (es)
CA (1) CA2394856C (es)
CL (1) CL2008000057A1 (es)
CO (1) CO5280226A1 (es)
CR (1) CR6674A (es)
CZ (1) CZ304925B6 (es)
DE (1) DE60045010D1 (es)
DK (1) DK1239872T3 (es)
ES (1) ES2353371T3 (es)
HU (1) HU230301B1 (es)
IL (2) IL150048A0 (es)
IN (1) IN247731B (es)
MX (1) MX264033B (es)
MY (1) MY124714A (es)
NZ (1) NZ519404A (es)
PH (1) PH12000003381B1 (es)
PL (1) PL203054B1 (es)
PT (1) PT1239872E (es)
RU (1) RU2272419C2 (es)
SK (1) SK287956B6 (es)
TW (1) TWI255189B (es)
UA (1) UA78486C2 (es)
WO (1) WO2001041785A2 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA78486C2 (uk) 1999-12-10 2007-04-10 Хемджен Корпорейшн Композиція для перорального введення птахам та тваринам для лікування або зниження ризику інфекції травного тракту (варіанти), її застосування (варіанти) та спосіб лікування або зниження ризику інфекцій травного тракту (варіанти)
US7247299B2 (en) * 2002-11-27 2007-07-24 Kemin Industries, Inc. Antimicrobial compounds from Bacillus subtilis for use against animal and human pathogens
US8703134B2 (en) 2003-05-15 2014-04-22 Iogenetics, Llc Targeted cryptosporidium biocides
US8394379B2 (en) * 2003-05-15 2013-03-12 Iogenetics, Llc Targeted cryptosporidium biocides
US20050014932A1 (en) * 2003-05-15 2005-01-20 Iogenetics, Llc Targeted biocides
US7566447B2 (en) * 2003-05-15 2009-07-28 Iogenetics, Llc Biocides
US8710012B2 (en) 2003-07-14 2014-04-29 Cls Therapeutics Limited Method for treating oncological diseases
US8431123B2 (en) 2003-07-14 2013-04-30 Cls Therapeutics Limited Method for treating systemic bacterial, fungal and protozoan infection
US8388951B2 (en) 2003-07-14 2013-03-05 Cls Therapeutics Limited Method for treating systemic DNA mutation disease
AU2005332655A1 (en) * 2004-10-20 2006-12-14 Iogenetics, Llc Biocides
US8916151B2 (en) 2005-04-25 2014-12-23 Cls Therapeutics Limited Method for treating a reduction of fertility
SI1973561T1 (sl) 2005-12-15 2011-07-29 Chemgen Corp Encimi, ki zmanjĺ ujejo imunski stres
PL2095825T3 (pl) 2006-11-28 2011-12-30 Cls Therapeutics Ltd Sposób leczenia ludzkich chorób związanych ze zwiększoną zawartością kwasu deoksyrybonukleinowego w przestrzeniach pozakomórkowych i tkankach i preparat leczniczy do przeprowadzenia tego sposobu
HUE025717T2 (en) * 2007-06-08 2016-04-28 Australian Poultry Crc Pty Ltd Clostridium NetB toxin
BRPI0820818A2 (pt) * 2007-12-20 2015-06-16 Danisco Us Inc Controle e prevenção enzimática de biofilme
DK2254591T3 (da) * 2008-02-08 2017-11-06 Prothera Inc Inhibering eller behandling af gastrointestinal biofilm
PT2814331T (pt) 2012-02-16 2019-02-12 Elanco Us Inc Métodos e composições para redução do impacto ambiental de resíduos animais
US10617743B2 (en) 2014-06-19 2020-04-14 Cls Therapeutics Limited Method to improve safety and efficacy of anti-cancer therapy
TWI656872B (zh) 2014-11-13 2019-04-21 美商益農美國公司 甲基鹽黴素於豬飼料中之抗病毒效果
EP3297657B1 (en) 2015-05-22 2020-03-25 GENKIN, Dmitry Dmitrievich Extracellular dna as a therapeutic target in neurodegeneration
CN106119221A (zh) * 2016-06-28 2016-11-16 浙江省农业科学院 磷脂酰肌醇特异性磷脂酶c基因、载体、工程菌及应用
CN106318925B (zh) * 2016-08-19 2021-04-02 浙江省农业科学院 利用枯草芽孢杆菌高效表达pi-plc基因的方法
CN106615691B (zh) * 2016-10-11 2019-07-02 上海国龙生物技术集团有限公司 一种抗感染酶复合剂及其在饲料中的应用
US10501730B2 (en) * 2017-05-30 2019-12-10 Ab Enzymes Oy Mannanase variants
EP3740581A4 (en) 2018-01-16 2021-10-27 CLS Therapeutics Limited TREATMENT OF DISEASES BY LIVER EXPRESSION OF AN ENZYME WITH DESOXYRIBONUCLEASE (DNASE) ACTIVITY
MX2020009045A (es) * 2018-03-02 2020-10-12 Evonik Operations Gmbh Procedimiento in vitro para detectar disfuncion de la barrera intestinal en animales mediante la determinacion de ovotransferrina.
RU2720471C1 (ru) * 2019-03-21 2020-04-30 Федеральное Государственное бюджетное научное учреждение "Федеральный научный центр биологических систем и агротехнологий российской академии наук" Кормовая добавка для цыплят-бройлеров

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1509866A (en) 1975-06-10 1978-05-04 Johnson & Johnson Enteric coated digestive enzyme compositions
JPS5534039A (en) 1978-08-30 1980-03-10 Hiroo Ikezawa Preparation of phsophatidylinositol phospholipase c from bacillus thuringiensis
WO1987000196A1 (en) 1985-07-09 1987-01-15 Quadrant Bioresources Limited Protection of proteins and the like
US5049379A (en) 1987-07-27 1991-09-17 Wisconsin Alumni Research Foundation Fungicidal toxin and method and inoculum for controlling root rot and damping off
US4877738A (en) 1986-07-25 1989-10-31 Wisconsin Alumni Research Foundation Biological control of damping off and root rot and inoculum preparation therefor
JPH0338530A (ja) * 1989-07-03 1991-02-19 Ajinomoto Co Inc 抗真菌剤
US5487897A (en) * 1989-07-24 1996-01-30 Atrix Laboratories, Inc. Biodegradable implant precursor
DK0531437T3 (da) * 1990-05-29 1998-08-31 Chemgen Corp Hemicellulasetilskud med henblik på at forbedre energiudnyttelsen af hemicelluloseholdige levnedsmidler og dyrefoder
EP0477739A3 (en) 1990-09-27 1992-12-09 F. Hoffmann-La Roche Ag Glycosyl-phosphatidylinositol-specific phospholipase d
JPH07184642A (ja) * 1993-12-27 1995-07-25 Toagosei Co Ltd ホスホリパーゼcの生産方法
MY134684A (en) * 1995-05-15 2007-12-31 Gist Brocades Bv Application of phospholipases in animal feed
EP0743017B1 (en) * 1995-05-15 2004-09-29 DSM IP Assets B.V. Application of phospholipases in animal feed
JPH08332032A (ja) * 1995-06-12 1996-12-17 Showa Denko Kk 動物経口物用酵素剤及びその用途
JP3914585B2 (ja) * 1995-10-19 2007-05-16 イーエヌ大塚製薬株式会社 マクロファージ一酸化窒素産生亢進剤
CN1092495C (zh) * 1996-05-03 2002-10-16 开姆根有限公司 半纤维素酶在低热焓饲料中的应用
US6162473A (en) * 1996-05-03 2000-12-19 Chemgen Corporation Hemicellulase use in feeds with low caloric content
JPH1045581A (ja) * 1996-07-29 1998-02-17 Hideyo Yamaguchi 好中球機能低下抑制剤又は感染防御剤
WO1998018912A1 (en) * 1996-10-31 1998-05-07 Novo Nordisk A/S Novel phospholipase, production and use thereof
AU753232B2 (en) 1998-10-15 2002-10-10 Dsm N.V. Antimicrobial enzymes in animal feed
UA78486C2 (uk) 1999-12-10 2007-04-10 Хемджен Корпорейшн Композиція для перорального введення птахам та тваринам для лікування або зниження ризику інфекції травного тракту (варіанти), її застосування (варіанти) та спосіб лікування або зниження ризику інфекцій травного тракту (варіанти)
US20020116028A1 (en) * 2001-02-20 2002-08-22 Wilson Greatbatch MRI-compatible pacemaker with pulse carrying photonic catheter providing VOO functionality

Also Published As

Publication number Publication date
AU2577601A (en) 2001-06-18
SK8262002A3 (en) 2002-12-03
ATE481981T1 (de) 2010-10-15
NZ519404A (en) 2004-05-28
MX264033B (es) 2009-01-22
IN247731B (es) 2011-05-13
CN102172262A (zh) 2011-09-07
IN2002DE00585A (es) 2009-03-20
US7723091B2 (en) 2010-05-25
DE60045010D1 (de) 2010-11-04
CN1433319A (zh) 2003-07-30
TWI255189B (en) 2006-05-21
CN101327320A (zh) 2008-12-24
PL356175A1 (en) 2004-06-14
MY124714A (en) 2006-06-30
HUP0203402A3 (en) 2004-12-28
RU2272419C2 (ru) 2006-03-27
EP1239872B1 (en) 2010-09-22
AR026764A1 (es) 2003-02-26
CA2394856C (en) 2011-05-10
WO2001041785A2 (en) 2001-06-14
CL2008000057A1 (es) 2008-03-14
CR6674A (es) 2007-02-22
SK287956B6 (sk) 2012-07-03
IL150048A0 (en) 2002-12-01
KR100639746B1 (ko) 2006-10-30
EP1239872A2 (en) 2002-09-18
KR20020069204A (ko) 2002-08-29
HU230301B1 (hu) 2015-12-28
US20040223961A1 (en) 2004-11-11
UA78486C2 (uk) 2007-04-10
PL203054B1 (pl) 2009-08-31
CO5280226A1 (es) 2003-05-30
US20020048576A1 (en) 2002-04-25
US6780628B2 (en) 2004-08-24
IL150048A (en) 2016-09-29
PT1239872E (pt) 2010-12-03
CN102172262B (zh) 2014-03-05
BRPI0016231B8 (pt) 2021-05-25
HUP0203402A2 (hu) 2003-02-28
CZ20022007A3 (cs) 2002-11-13
AU782831B2 (en) 2005-09-01
PH12000003381B1 (en) 2010-04-16
BR0016231A (pt) 2003-06-24
WO2001041785A3 (en) 2002-01-24
MXPA02005735A (es) 2003-10-14
CZ304925B6 (cs) 2015-01-28
CA2394856A1 (en) 2001-06-14
JP2003520207A (ja) 2003-07-02
ES2353371T3 (es) 2011-03-01
DK1239872T3 (da) 2010-10-25
BRPI0016231B1 (pt) 2016-10-04
JP4871473B2 (ja) 2012-02-08

Similar Documents

Publication Publication Date Title
AR089799A2 (es) Composicion que comprende enzimas y usos para la fabricacion de una composicion para tratar o disminuir el riesgo de infecciones del tracto digestivo
Mizuno Shiitake, Lentinus edodes: functional properties for medicinal and food purposes
AR025599A1 (es) Metodo para mejorar la piel y el pelaje de mascotas
KR101132392B1 (ko) 발효 태반 조성물 및 그 용도
DE69114498D1 (de) Kurzbettige, einfach ungesättigte fettsäuren enthaltende nahrungsmittel und pharmazeutische zusammensetzungen sowie deren anwendungen.
US5372942A (en) Protease K resistant arginine deiminase, its method of preparation and its use as an anti-neoplastic agent
WO2002083120A3 (en) Medium-chain length fatty acids, glycerides and analogues as neutrophil survival and activation factors
CN110326708B (zh) 一种功能性混合添加剂及其应用
CN100421573C (zh) 一种畜禽肉质改进剂
KR100330993B1 (ko) 액상 사료 첨가제 및 이의 제조방법
EP0203649A3 (en) Pharmaceutic composition based on diphoshonates for the treatment of the arthrosis
Lillehoj et al. Calcium montmorillonite-based dietary supplement attenuates necrotic enteritis induced by Eimeria maxima and Clostridium perfringens in broilers
EP0308197A3 (en) Method for stimulating the immune system
HU183897B (en) Method for improving the milk production
JPH05229959A (ja) 鉄吸収促進組成物
JP4056099B2 (ja) 水生動物の寄生生物性疾患の予防および治療剤
WO1999062355A1 (en) Piglet feeding method
CA2425319A1 (en) Treatment and prophylaxis of diseases and infections of pigs and poultry
CN114831248A (zh) 一种生物脱霉剂及其制备方法和应用
CN105454695A (zh) 一种用于防治猪腹泻的饲料添加剂
EP0240274A3 (en) Avermectins as growth promotant agents
EP0343671A2 (en) Pharmaceutical composition for the treatment of skin wounds
JP2003304846A (ja) 飲料または食品
JPH1070960A (ja) セレン含有菌体の用途
KR102609443B1 (ko) 동애등에, 주스박, 난각을 포함하는 애완동물용 사료

Legal Events

Date Code Title Description
FC Refusal